gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin sae dmd gt get rmat
highlight week june june unrat present initi phase ib data parent project
muscular dystrophi annual confer gene therapi gt duchenn muscular
dystrophi dmd result patient age year show arguabl broadli compar efficaci mini-
dystrophin product unrat gt howev seriou advers event sae
report hospit complement system activ nausea/vomit compar sarepta
gt note episod complement activ associ differ dmd program
neutral-r solid bioscienc krystal biotech buy chardan top pick announc
posit data phase ii trial updat phase trial topic
base gt recess dystroph epidermolysi bullosa rdeb use studi
associ high rate wound closur close vs placebo advers event
month treatment view data newly-announc fda regen medicin advanc therapi
rmat design posit buy present peripher nerv
societi pn annual meet data phase open-label extens trial patisiran
onpattro show maintain revers diseas progress patient hereditari attr hattr amyloidosi
polyneuropathi alnylam also present indirect treatment comparison onpattro tegsedi inotersen base
phase apollo neuro-ttr studi respect result show favor treatment effect onpattro
versu tegsedi endpoint includ qol bodi mass index polyneuropathi disabl score
look forward june juli june juli european academi neurolog ean host annual
congress oslo program featur repres unrat
unrat unrat juli intern societi thrombosi
haemostasi isth host annual congress melbourn program includ repres biomarin
unrat uniqur buy chardan top pick
weekli price move vivo genet medicin aav srna mrna vivo gene edit
srna mrna mm vivo gene edit mm contributor qure buy mm
upcom chardan genet medicin event contact chardan rsvp
gene express us patent offic declar interfer crispr patent disput
june patent trial appeal board ptab declar interfer patent applic patent
relat use crispr gene edit technolog univers california broad institut
come septemb decis us court appeal uphold februari rule
interference-in-fact neither cancel final refus either parti claim uc license includ carib
bioscienc privat crispr buy intellia buy license broad includ
edita medicin buy privat recal uc file lawsuit claim interfer ip
broad decis meant court believ patent broad regard crispr edit
eukaryot cell describ differ invent uc berkeley work
pleas refer import disclosur inform regul analyst certif found page report
understand current declar focus specif invent crispr edit eukaryot cell
directli request uc broad uc discuss interfer ptab august
event settlement reach hear would take place month continu close
follow develop crispr ip disput note chardan gene edit framework cgef given
increas complex crispr ip landscap expect eventu satisfactori resolut ip disput via
settlement cross-licens agreement
buy pt phase ii data rmat design june amusa
announc posit result phase ii trial posit updat
phase trial topic gt rdeb view newly-announc receipt rmat
design signific posit timelin note krystal market cap modest
rel compani prime and/or rmat/btd design reiter would surpris
krystal market cap cross billion news increas pt
krystal demonstr impress wound closur data albeit small number patient
studi timepoint inflamm irrit wound sae antibodi respons
transgen use drug-rel advers event record
wound close trial wound remain open chronic deep wound remain
open year prior trial placebo-tr wound remain fulli open timepoint
krystal intend initi pivot phase trial may file bla addit patient data
phase result would give us even greater confid rdeb
genet medicin news june june
buy present result pn open-label extens studi rnai tx onpattro june
present pn annual meet interim result global phase open-label
extens trial onpattro patient hattr polyneuropathi
data present patient previous particip phase ii open-label extens
apollo phase trial serum transthyretin ttr level reduc approxim
month post-treat initi maintain time patient placebo arm
apollo studi start treatment onpattro rapid progress diseas among placebo patient
also halt major patient revers howev return baselin seen placebo
patient highlight import need earli treatment patisiran patient treatment month
sustain improv neuropathi impair qualiti life measur seen
alnylam also present addit analys apollo show patient diseas progress
tafamidi discontinu tafamidi may benefit treatment onpattro indirect treatment
comparison onpattro tegsedi inotersen show favor treatment effect patisiran rel inotersen
across endpoint evalu includ qol bodi mass index polyneuropathi disabl score
nk unrat initi pi trial nk cell-bas car-t tx t-hank patient solid tumor june
curevac privat announc appoint new member advisori board june
buy announc price mm public offer common stock june
agtc neutral appoint dr theresa heah brian krex gener counsel june
cobra biolog privat announc complet viral vector collabor symbiosi privat june
umichigan publish gt retin dystrophi june
gener privat announc appoint dr katherin fitzgerald advisori board june
encod tx privat announc mm seri round aav-bas gt dravet syndrom june
oxb gb unrat announc collab santen unrat inherit retin diseas june
xon unrat announc patient dose pi/ib trial car-t tx r/r aml june
unrat announc appoint dr paulu svp regulatori affair june
unrat complet enrol piii trial dna immuno-tx hpv cervic cancer june
xcur buy announc preclin data biodistribut central nervou system june
page
unrat complet enrol phase trial viral tx control nivolumab june
unrat initi phase ii trial control libtayo recurr glioblastoma june
seel unrat announc acquisit right duke gt program parkinson diseas june
buy receiv track design rnai tx aro-aat antitrypsin defici june
unrat announc initi dystanc phase ii/iii trial aso suvodirsen dmd june
adap unrat announc cfa adrian rawcliff succeed jame nobl ceo june
arct buy receiv orphan drug design mrna tx over-the-counter defici june
unrat announc chang leadership team june
onc unrat receiv exclus right dfci car-t cell therapeut solid tumor june
unrat announc stock ad russel microcap index june
unrat report result year end march provid busi updat june
unrat present data phase ib trial gt dmd june
present data annual confer on-going phase ib trial
gt dmd also announc plan initi phase trial dmd
patient receiv intraven dose vg/kg vg/kg month post-
treatment percentag mini-dystrophin-posit muscl fiber patient receiv low dose
patient receiv high dose mean express level mini-dystrophin normal defin
mean concentr fmol/mg protein patient receiv low dose
normal patient receiv high dose patient reach year post-treat mean improv
northstar ambulatori assess nsaa score point
common advers event nausea vomit decreas appetit tired and/or fever report
patient sae report patient hospit day receiv intraven antiemet
replac fluid patient admit pediatr icu day intermitt hemodialysi iv
dose complement inhibitor develop rapid antibodi respons activ complement system
associ acut kidney injuri hemolysi reduc platelet count result sae addit
patient dose addit safeti monitor obtain approv clinic research site
gt use mini-dystrophin approach similar micro-dystrophin approach use sarepta therapeut
sarepta gt show rel similar superior
efficaci dose vg/kg though comparison difficult make given differ assay use howev
sarepta gt far associ sae solid gt face safeti
complic complement activ hy law dose vg/kg vg/kg note
path market could exist competitor unabl adequ suppli market
result complement activ us lower elimin possibl solid sae
manufactur relat extent solid show better data efficaci better stock perform could ahead
mit publish identif synthet promot enhanc cell-stat specif spec june
unrat present initi data ean pi trial cell tx multipl sclerosi june
unrat announc european label expans aso therapi spinraza sma june
compani mention report
page
page
select catalyst genet medicin coverag
figur alnylam arrowhead dicerna meira gtx expect initi trial
select optim dose xlmtm
dcr-phxc initi long-term registr roll-ov studi ph
file ind cta pomp diseas
aro-aat initi phase ii/iii studi liver diseas
releas cgmp manufactur phase i/ii studi
initi phase i/ii trial
aav-rpgr prelim dose escal data phase i/ii trial xlrp
initi trial malign
complet ind-en studi diseas
dose patient phase studi mp
lumasiran initi illuminate-b -c phase trial
givosiran file applic ahp
provid updat phase i/ii studi hemophilia
report phase i/ii data
page
select catalyst genet medicin coverag
file ind pomp diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase i/ii clinic trial huntington diseas
report dose escal data pi/ii trial achm/xlrp
report preliminari data phase i/ii studi batten diseas
initi phase i/ii trial dmd
submit ema lhon
report interim efficaci readout phase oval trial ovarian cancer
xlrp report interim data expans arm phase i/ii trial xlrp
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
provid earli data cohort phase i/ii pioneer trial n- rp
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
top-lin phase ii data treat deb patient chronic wound
initi phase i/ii trial autosom recess congenit ichthyosi
report interim phase i/ii data rix nidcr/nih
initi dose phase trial hemophilia
initi phase i/ii trial
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
updat dose escal pi/ii ignit trial dmd
provid updat initi safeti studi hemophilia without inhibitor
 aro-enac file clear cell renal cell carcinoma cystic fibrosi
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
submit ind methylmalon acidemia mma
present preclin data new gt program fabri pomp defici
initi phase i/ii trial sjogren syndrom
file ind initi phase i/ii trial al
file ind initi phase i/ii trial wet
file ind huntington diseas program
provid follow-up data piib dose-confirm studi hemb
present top-lin data phase i/iia clinic trial wet
initi pivot trial
 fc report final analysi phase trial rhgg
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
figur alnylam/mdco meira gtx solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
file ind rett syndrom
initi phase i/ii trial leukocyt adhes deficiency-i
initi phase trial recess dystroph epidermolysi bullosa
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
file ind inherit amyotroph later sclerosi
begin patient dose phase trial
initi pivot phase trial rdeb
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
valrox present full piii top-line data hem
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
zolgensma anticip approv eu
initi phase ii trial /- cemiplimab cutan squamou cell carcinoma
initi phase trial /- solid tumor
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
present data phase portion solid tumor trial /- nivolumab
valrox submit bla pend fda feedback hemophilia
begin dose patient investigator-sponsor phase i/ii trial cystinosi
initi phase i/ii trial type gaucher diseas
bmn file ind phenylketonuria pku
initi phase ib trial beta-thalassemia
initi phase ii/iii trial dmd
initi phase studi pyruv kinas defici pkd
initi phase trial multipl myeloma
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
rituximab report preliminari phase cohort expans data r/r nhl
micro-dystrophin initi pivot trial duchenn muscular dystrophi
hmaxi-k initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
zolgensma complet strong phase trial pre-symptomat sma type
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
ptc-fa file ind friedreich ataxia fa enter clinic
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end june vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm genet therapytickerratingccm ptupsideclosechang changemc mm regulu gene editingtickerratingccm ptupsideclosechang changemc mm intellia pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name rgl model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti ntech curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan poseida recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
